Articles tagged with Pancreatic Cancer
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new mechanism of resistance to KRAS inhibitors in pancreatic cancer, suggesting an opportunity to make the treatment more effective. The study found that a more aggressive subtype of pancreatic tumor is likely to respond well to KRAS inhibitors.
Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.
Researchers identified nidogen-2 as a key driver of pancreatic cancer progression and metastasis. Blocking this molecule enhanced chemotherapy effectiveness and reduced spread in mouse models, suggesting a promising new treatment approach.
Scientists at Stanford University discovered that pancreatic cancer cells become resistant to chemotherapy due to stiff tissue and high hyaluronic acid levels. By altering the matrix, they found it possible to make cancer cells sensitive to chemotherapy again.
The article reviews recent advances in applying artificial intelligence to oncology, showcasing promising improvements in cancer care. The authors emphasize the need for interdisciplinary collaboration, rigorous validation, and ethical principles to harness AI's potential.
Researchers at Weill Cornell Medicine have identified cellular and molecular markers that can predict when pancreatic cancer will spread to the liver or other organs. The study found that patients with early-stage pancreatic cancer who showed signs of immune exhaustion were more likely to develop liver metastases.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
Researchers at Johns Hopkins Medicine have developed a 3D genomic profiling technique to identify small precancerous lesions in the pancreas, which can lead to aggressive pancreatic cancers. The study provides the most detailed 3D map of precancerous lesions in the human pancreas to date.
Researchers have discovered that a protein called MED12 plays a critical role in pancreatic cancer's development, particularly in basal-like cells. The study builds on decades of research at Cold Spring Harbor Laboratory, which previously identified the importance of p63 for basal cell formation.
A team of researchers has identified the CDA gene as a key player in immunotherapy resistance in pancreatic cancer. Inhibiting this gene improves T-cell infiltration and increases the effectiveness of immunotherapy in a type of pancreatic cancer called PDAC.
A comprehensive molecular portrait of KRAS has been established, revealing its key role in pancreatic cancer progression and resistance to treatment. The study identifies ERK as a critical regulator of KRAS activity, with implications for developing targeted therapies.
Researchers developed a human pancreatic cancer fibrotic barrier model to assess treatment strategies and test efficacy of therapeutic interventions. Inhibition of ROCK2 pathway resulted in reduced ECM remodeling and improved tissue permeability for drugs, highlighting its potential for enhancing drug delivery in PDAC.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
The phase 2 clinical trial of BXCL701 in combination with pembrolizumab showed a 50% progression-free survival rate and significant reductions in CA19-9 markers, indicating potential anti-cancer effects. The treatment has also shown low blood pressure as the main side effect.
Researchers found that statins, specifically pitavastatin, can suppress inflammation in the skin and pancreas by blocking interleukin-33 production. This inhibition reduces the risk of chronic pancreatitis and pancreatic cancer.
Researchers at Hollings Cancer Center have identified a promising therapeutic strategy to combat pancreatic cancer. By simultaneously blocking HSP70 and autophagy, the growth of pancreatic tumors can be slowed, offering new hope for treatment.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers have developed a breakthrough therapy that can adapt CAR-T cell therapy to target solid tumors, potentially transforming cancer treatment. The therapy uses a novel antibody and costimulatory protein to activate T cells, overcoming the challenges of immune suppression in solid tumors.
Researchers at the University of Wisconsin-Madison have developed a novel approach to treating pancreatic cancer using nano-drugs delivered via bacteria. The treatment bypasses the dense collagen barrier surrounding tumors, allowing for more effective delivery of immunotherapies.
Researchers discovered that the anatomical location of pancreatic tumors impacts treatment outcomes, suggesting a tumor-location-based model for improving patient care. The findings may lead to more specific treatment plans and better immunotherapy effectiveness.
The ECOG-ACRIN Cancer Research Group will present late-breaking findings on prostate cancer, breast cancer, and pancreas cancer at ASCO 2024. These studies include optimal chemotherapy for Black women with breast cancer and results from the first randomized national trial in older adults with pancreas cancer.
A new case report uses longitudinal multi-omics monitoring to detect a precancerous pancreatic tumor in a patient. The study highlights the potential of blood-based LMOM for early detection and personalized medicine, warranting further translational research.
Researchers discovered that liver cells secrete SAA proteins, which hinder T cell infiltration and attack tumors. Deleting SAA proteins increased survival times and likelihood of cures in mice with pancreatic tumors.
The PRECEDE study found that nearly 80% of participants in the highest-risk cohort completed baseline imaging, highlighting the feasibility of improving early detection and prevention for pancreatic cancer. Researchers recommend sorting individuals into three groups based on family history and genetic mutations to tailor surveillance.
A new study reveals that 'crosstalk' between pancreatic cancer cells and macrophages is the first step towards the onset of cachexia. The research provides evidence of an underlying mechanism for the development of this debilitating muscle-wasting condition, which affects pancreatic cancer patients.
The National Science Foundation has awarded Amplified Sciences a $275,000 Phase 1 Small Business Innovation Research grant to develop novel ultrasensitive optical reporter platform technology for early detection of pancreatic cancer. The company aims to improve diagnosis and treatment outcomes with its multiplexing capabilities.
A new class of oral medications targeting RAS proteins has shown promising results in preclinical models, potentially offering novel treatment options for nearly all pancreatic tumors. The inhibitors performed well across various models, with minimal impact on normal cells.
A novel exosome-based liquid biopsy approach has been developed to detect pancreatic cancer at early stages. The method combines eight microRNAs uniquely found in exosomes shed from pancreatic cancers with five cell-free DNA markers, achieving a 97% detection rate for stage 1-2 cases.
Researchers found that an individualized neoantigen-specific mRNA vaccine, autogene cevumeran, can induce a robust immune response in patients with resectable pancreatic cancer. After a median follow-up of three years, the treatment was associated with a significantly longer median recurrence-free survival compared to those who did not...
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
Cold Spring Harbor Laboratory researchers developed Accelerated SuFEx Click Chemistry to create over 150 new molecular compounds, including derivatives of complex natural molecules. These compounds show promise as leads for developing antibiotics and cancer therapies.
Researchers at the University of Oklahoma have discovered how pancreatic cancer cells exploit an acidic environment to their advantage, finding ways to survive and grow. This knowledge is crucial for developing new therapeutic approaches to target the cancer.
Researchers at Mass General Cancer Center presented advancements in rapid nucleic acid detection for cervical cancer screening using CRISPR technology. They also showcased improvements to CAR T cell therapy for pancreatic cancer, highlighting the importance of dynamic functional control to enhance its efficacy.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
Researchers at VUB discovered that targeting the xCT protein can reduce tumour growth while regulating inflammation and improving mood. This finding holds promise for a comprehensive approach to treating pancreatic cancer, a highly malignant form of the disease.
Research reveals a significant connection between oral bacteria and accelerated pancreatic cancer development in mice. Viable Porphyromonas gingivalis was found in the pancreas of healthy mice after gum application, causing changes in the organ's microbial balance.
A study published in Lancet Gastroenterology & Hepatology found that not placing a drain during distal pancreatectomy surgery improves patient outcomes. The study, involving 282 patients across ten Dutch and two Italian hospitals, demonstrated a significant reduction in postoperative pancreatic leaks and overall morbidity.
A recent study at Salk Institute evaluates the reliability of patient-derived organoids as a clinical model for pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by commercial extracellular matrix brands, but one product increases growth rate.
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
Researchers at Cold Spring Harbor Laboratory have uncovered a mechanism involved in pancreatic cancer transformation, discovering that low-grade pancreatic cancer cells depend on mucus to survive and thrive. This knowledge could help set the stage for future diagnostic or therapeutic strategies.
A University of Oklahoma researcher has made promising discoveries on the role of vitamin B6 in pancreatic cancer. By understanding how pancreatic cancer cells deplete vitamin B6, she developed a three-part strategy to impede their growth and enhance immune function.
A new off-the-shelf vaccine has shown promise in treating pancreatic and colorectal cancers in patients with KRAS mutations. The study found that the vaccine significantly decreased tumor biomarkers and produced strong T-cell responses, leading to a reduced risk of relapse and death.
New research led by Johns Hopkins Medicine reveals that age-related changes in fibroblast cells enable pancreatic cancer tumor growth. The study found that older patients have poorer prognoses due to altered proteins released by fibroblasts, which promote cancer cell growth and spread.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
A study published in Oncotarget has identified specific mutational and therapeutic landscapes of pancreatic cancer in the Russian population. By applying machine learning models to full exome individual data, researchers received personalized recommendations for targeted treatment options for each clinical case.
Scientists have discovered that pancreatic cancer hijacks the brain-building protein Engrailed-1, leading to faster and deadlier metastasis. By targeting this aberrant protein, researchers may be able to develop personalized therapies and slow cancer progression.
Researchers discovered that blocking efferocytosis pathway prevents immunosuppressive activity in macrophages, restoring T cell activation and reducing metastatic tumour burden. The study found PDAC metastases to show high levels of immunosuppressive macrophages, promoting tumour growth.
Researchers propose a novel augmentation regimen, IPIAD, combining five generic non-oncology drugs with standard chemotherapy for pancreatic ductal adenocarcinoma. The IPIAD regimen uses repurposed drugs like irbesartan and azithromycin to potentially slow disease growth and improve outcomes.
A study published in Advanced Science identified Engrailed-1 as a key factor promoting pancreatic cancer progression and metastasis. The researchers found that elevated Engrailed-1 levels were associated with severe pancreatic cancer, suggesting it as a potential target for therapies.
Researchers at the University of Oklahoma Health Sciences have developed a new imaging technique that can detect pancreatic cancer cells approximately 10 times more magnificently than current options. The approach combines contrast agent recognition with Multispectral Optoacoustic Tomography, enabling real-time detection and surgery pl...
Experts predict a significant increase in bowel cancer death rates among young adults in the EU and UK, driven by rising obesity and heavy alcohol consumption. Death rates are predicted to rise by 26% in men and nearly 39% in women in the UK, with similar increases seen in Italy and other European countries.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
A study from Dana-Farber Cancer Institute found that unintentional weight loss is associated with an increased risk of cancer diagnosis within the coming year. The research suggests that patients experiencing unexpected weight loss should see their doctor to consider possible causes, including cancer. Healthy weight loss can come from ...
Researchers found that the loss of RBFOX2 protein leads to increased cell migration, invasion, tumor development, and metastasis in pancreatic cancer. The study suggests alternative RNA splicing plays a critical role in pancreatic cancer progression.
A Phase I trial demonstrated that a vaccine targeting KRAS mutations delayed relapse in patients with high-risk pancreatic and colorectal cancer. The vaccine induced significant T cell responses, which correlated with reduced risk of relapse.
A new study found that Ga-68 FAPI PET imaging can effectively detect and stage pancreatic cancer, outperforming existing methods. The imaging modality also showed potential for future targeted radiopharmaceutical therapies.
A drug screening system modeling cancers with lab-grown tissues called organoids helped uncover a promising target for future pancreatic cancer treatments. Researchers identified an existing heart drug, perhexiline maleate, that powerfully suppresses the growth of pancreatic tumor organoids.